X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.
Lead Product(s): CELZ-201-DDT
Therapeutic Area: Neurology Product Name: AlloStem
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
CELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas. CELZ-201 leverages unique approach harnessing the power of PRDC to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, without immunosuppression.
Lead Product(s): CELZ-201
Therapeutic Area: Endocrinology Product Name: CELZ-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Syneos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2023
Details:
ImmCelz™ has been demonstrated effective in animal models of autoimmunity and is currently the subject of a pending IND filed by the Company with the FDA for the treatment of stroke victims.
Lead Product(s): Amniotic Fluid Derived Stem Cells
Therapeutic Area: Neurology Product Name: ImmCelz
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
The Company's ImmCelz® product utilizes a patient's own blood cells that have been "reprogrammed" in the laboratory by culturing with established universal donor stem cells, followed by re-infusion into the patient.
Lead Product(s): Amniotic fluid derived stem cells
Therapeutic Area: Neurology Product Name: ImmCelz
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2021
Details:
Creative Medical Technology Holdings reported that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz IND for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements.
Lead Product(s): Amniotic fluid derived stem cells
Therapeutic Area: Neurology Product Name: ImmCelz
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
The findings, which are revealed in a newly filed patent application, show that T regulatory cells are effective in the treatment of ovarian failure, lending scientific support to OvaStem® as it approaches FDA clinical trials.
Lead Product(s): OvaStem
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OvaStem
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
Company demonstrates that in addition to activating endogenous stem cells and t regulatory cells ImmCelz® induces surge of therapeutic protein HGF-1.
Lead Product(s): Amniotic fluid derived stem cells
Therapeutic Area: Neurology Product Name: ImmCelz
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
Creative Medical Technology has filed a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model.
Lead Product(s): Amniotic fluid derived stem cells
Therapeutic Area: Nephrology Product Name: ImmCelz
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
The data reported strongly supports the safety and potency of the JadiCell™, which also supports the validity of ImmCelz® which is 'powered by JadiCell™.
Lead Product(s): Mesenchymal Stem Cells
Therapeutic Area: Infections and Infectious Diseases Product Name: JadiCell
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
